Rich pharma companies, poor patients.
Pharmaceutical companies are getting rich on the backs of their patients. Don't believe me? Here's some proof.First we have an article from New Jersey on how Roche's profits are up 10% and its revenues are up 4% on profits from its breast cancer drugs. The company is now focusing on cancer drugs and hopes to find more high profit drugs as generics come available for drugs such as Herceptin.  By the way, their cancer drugs cost between $70,000 and $100,000+ annually per patient.If you ask a pharma company you get the standard lines: 'no one pays those prices', 'they are covered by insurance', 'we do have programs for t...
Source: Caroline's Breast Cancer Blog - July 28, 2013 Category: Cancer Tags: patient rights medication costs Source Type: blogs

India To Issue Compulsory Licenses On Cancer Meds
In the latest move destined to make global drugmakers bristle, the Indian government is taking steps to issue compulsory licenses on three widely used cancer medications in hopes of making these treatments more affordable to a wider swath of its population, according to The Indian Express. The effort comes a year after India awarded a compulsory license to a generic drugmaker to produce a lower-cost version of a Bayer drug called Nexavar that is used to treat kidney and liver cancer, a step that was regarded as a landmark decision at the time and was predicted to usher in still more licenses. After the license was issued, ...
Source: Pharmalot - January 14, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Bayer Breast Cancer Bristol Myers Squibb Compulsory License Gleevec Glivec Herceptin Novartis Roche Source Type: blogs